Rhine Pharma

Rhine Pharma is a private, pre-revenue biotech spin-out from Telix Pharmaceuticals and Heidelberg University Hospital, specializing in accessible radiotheranostics. Its core strategy leverages generator-produced isotopes (Rhenium-188 for therapy, Technetium-99m for imaging) to enable decentralized production, particularly beneficial for regions with limited nuclear medicine infrastructure. The company's advanced pipeline is centered on a PSMA-targeting small molecule, with its therapeutic candidate (RHN001-Tx) currently in a Phase 1/2a clinical trial in South Africa.

A proprietary platform for developing theranostic radiopharmaceuticals based on generator-produced radioisotopes, specifically Rhenium-188 for therapy and Technetium-99m for imaging. This enables decentralized, on-site production suitable for regions with limited radiopharmacy infrastructure.

Rhine Pharma competes in the crowded prostate cancer theranostics space, dominated by Novartis's approved Pluvicto®. Its key differentiation is not necessarily superior efficacy, but rather a potentially more accessible and decentralized production model using Rhenium-188, contrasting with the complex supply chains of Lutetium-177 or Actinium-225 based therapies.